News

Orally administered lenalidomide, a second-generation antimyeloma thalidomide analog, is a workhorse in contemporary management of multiple myeloma:...

As new treatments for multiple myeloma have extended patient survival—from an average of three years to more than 10 in some cases—physicians and...

Multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS), a precursor to MM, are 2 to 3 times more common in African...

Until now, myeloma patients whose cancer was resistant to commonly used treatment methods and drugs had nowhere to turn. But a Phase 2 CAR T-cell...

Increasing incidence of cancer and rising number of patients showing response failure to alternative treatments is expected to foster growth of the...

On January 3, 2019, Takeda announced multiple research collaborations involving the development of chimeric antigen receptor T-cell (CAR-T)...

Multiple myeloma is a type of blood cancer that affects the plasma cells located in the bone marrow of the body. During an infection, when B cells...

The 'Global and Southeast Asia Multiple Myeloma Drugs Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the...

Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have failed or...

The anti-BCMA CAR T-cell therapy bb21217 demonstrated an objective response rate (ORR) of 83.3%, with a very good partial response (VGPR) or better...

AIMS: Multiple myeloma is a genomically complex haematological malignancy with many genomic alterations recognised as important in diagnosis,...

A therapeutic drug, called lenalidomide, has shown improved outcomes and survival rates in patients with a serious type of bone marrow cancer...